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Abstract
Methods: The aim of this prospective, observational cohort study was to determine the clinical and microbiological features,
outcome, and baseline variables predictive of death, in Vietnamese adults with HIV-associated tuberculous meningitis
(TBM). 58 patients were admitted to the Hospital for Tropical Diseases in Ho Chi Minh City and underwent routine clinical
and laboratory assessments. Treatment was with standard antituberculous therapy and adjunctive dexamethasone;
antiretroviral therapy was not routinely available. Patients were followed up until the end of TB treatment or death.
Results: The median symptom duration was 11 days (range 2–90 days), 21.8% had a past history of TB, and 41.4% had
severe (grade 3) TBM. The median CD4 count was 32 cells/mm
3. CSF findings were as follows: median leucocyte count
438610
9cells/l (63% neutrophils), 69% smear positive and 87.9% culture positive. TB drug resistance rates were high (13%
mono-resistance 32.6% poly-resistance 8.7% multidrug resistance). 17% patients developed further AIDS-defining illnesses.
67.2% died (median time to death 20 days). Three baseline variables were predictive of death by multivariate analysis:
increased TBM grade [adjusted hazard ratio (AHR) 1.73, 95% CI 1.08–2.76, p=0.02], lower serum sodium (AHR 0.93, 95% CI
0.89 to 0.98, p=0.002) and decreased CSF lymphocyte percentage (AHR 0.98, 95% CI 0.97 to 0.99, p=0.003).
Conclusions: HIV-associated TBM is devastating disease with a dismal prognosis. CSF findings included CSF neutrophil
predominance, high rates of smear and culture positivity, and high rates of antituberculous drug resistance. Three baseline
variables were independently associated with death: increased TBM grade; low serum sodium and decreased CSF
lymphocyte percentage.
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Introduction
Tuberculous meningitis (TBM) is the most severe form of
Mycobacterium tuberculosis infection, and carries a high morbidity and
mortality [1]. HIV infection is associated with an increased risk of
developing tuberculosis (TB), particularly extra-pulmonary disease
[2]. The clinical features of TBM mimic other chronic
meningoencephalitides, making diagnosis difficult. The classical
cerebrospinal fluid (CSF) findings include a lymphocytic CSF
pleocytosis, raised protein and low CSF to blood glucose ratio.
The diagnosis of TBM usually relies on the detection of acid-fast
bacilli in CSF, a simple, affordable method with low diagnostic
sensitivity in routine laboratories. Culture of M. tuberculosis from
the CSF is the diagnostic gold standard but is expensive, requires
laboratory infrastructure and expertise, and takes too long to guide
initial patient management.
Despite the availability of highly effective antituberculous
chemotherapy, the outcome from TBM remains poor [3,4]. The
optimal treatment of TBM has not been determined by
randomized controlled trials, although a number of clinical
guidelines exist [5–7]. Multi-drug resistant tuberculosis (MDR-
TB) has long been recognized to be associated with institutional
outbreaks in HIV-infected patients [8]. Outside the outbreak
setting, the data on the association between HIV infection and
MDR-TB is limited [8]. More recently an outbreak of extensively
drug resistant tuberculosis (XDR-TB) has been been reported [9].
Patients with MDR-TB have lower cure rates and higher mortality
rates that patients with drug susceptible TB [10–13].
The treatment of HIV-associated TB is similar to TB in HIV-
negative patients with some important differences; these include
the drug interactions between rifamycins and antiretrovirals,
paradoxical reactions or immune reconstitution inflammatory
syndrome (IRIS) [14–17] and the potential to develop rifamycin
resistance with highly intermittent therapy [18]. Although
antiretroviral therapy (ART) is recommended for all HIV patients
presenting with TB, the optimal time to initiate ART is unknown
[19]. Two retrospective studies have shown that starting ART
early in severely immunosuppressed patients with TB is associated
with decreased mortality and a lowering of rates of progression
[20,21].
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th out of 22 countries defined as high burden
for tuberculosis (TB) by the World Health Organization (WHO),
with an estimated incidence of 178/100,000 population per year
[22]. The estimated prevalence of multi-drug resistant tuberculosis
(MDR-TB) in Vietnam was 2.3% in 1996 [22]. Given that directly
observed therapy short course (DOTS) coverage and case
detection and cure rates in Vietnam have been exceeded WHO
targets for many years, a fall in the incidence rate might have been
expected. It is unclear why no such decline is evident, but lack of
contact tracing, no treatment for latent TB infection, an
unregulated private sector for TB treatment and an emerging
HIV epidemic may all be possible contributors. The first HIV case
was reported in Vietnam in 1990. Since then the number of
reported HIV infections has escalated and the total number of
people living with HIV was estimated to be 260,000 (range
150,000–430,000) at the end of 2005 [23]. While the national
adult HIV prevalence was estimated to be 0.5% in 2005, it exceeds
1% in certain provinces.
In view of the high prevalence of tuberculosis and escalating
HIV epidemic we conducted a prospective, observational cohort
study to determine the clinical and microbiological features and
outcome of HIV-infected patients presenting with TBM to the
Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam and
to determine which baseline variables were associated with death.
Methods
Objectives
The aim of this study was to determine the clinical and
microbiological features, outcome, and baseline variables predic-
tive of death, in HIV-associated TBM.
Setting and study participants
Patients were admitted the Hospital for Tropical Diseases, Ho
Chi Minh City, Vietnam. This 500-bedded hospital acts as a
primary, secondary and tertiary referral centre for infectious
diseases, and serves the population of southern Vietnam
(approximately 38 million).
Inclusion and exclusion criteria
The study inclusion criteria were age $15 years, HIV infection,
and clinically suspected TBM. Patients were excluded if there was
microbiological evidence of another central nervous system (CNS)
infection.
Consent procedures
Patients who were fully conscious gave written informed
consent. For patients who were unable to provide their own
consent, written informed consent was obtained from their relative
or, if no relative was available, from two independent physicians.
Ethical approval
The study was approved by the Oxford Tropical Research Ethics
Committee, UK, and the Scientific and Ethical Committee of the
Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam.
Patient assessment
All patients underwent routine clinical and laboratory assess-
ments, including CSF examination, chest radiography and cranial
imaging, if possible.
Patients were defined as having definite or probable TBM
according to the following criteria. Patients were classified as definite
TBM if the CSF was smear positive for acid-fast bacilli and/or
culture positive for M. tuberculosis. Patients were classified as probable
TBM if they fulfilled study entry criteria and had at least one of the
following four criteria: chest radiograph consistent with pulmonary
tuberculosis; other specimens (e.g. sputum, lymph node, gastric
washings) positive for acid-fast bacilli; evidence of extra-pulmonary
tuberculosis; computed tomography (CT) or magnetic resonance
imaging (MRI) evidence of tuberculous meningitis.
Severity of disease at presentation was assessed using the British
Medical Research Council TBM grade [24]; gradeI TBM is defined
as a Glasgow coma score (GCS) of 15 with no focal neurology; grade
IITBM asa GCS of15 with a focal neurologicaldeficit, or a GCS of
11 to 14 and grade III TBM is defined as a GCS of #10.
During the study period, patients were evaluated weekly for the
first 3 months, then every 3 months until withdrawal, loss to
follow-up, completion of TBM treatment, or death.
Microbiological investigations
Up to 10mls of CSF was collected in a sterile Universal
container and centrifuged at 4000xg for 15 minutes. Most of the
supernatant was removed and the deposit was re-suspended in
approximately 200 ml of supernatant. A portion of the deposit was
examined by Gram, India ink and Ziehl-Neelsen stains. The
remaining deposit was cultured on blood and chocolate agar for
bacteria and fungi, and on Lo ¨wenstein-Jensen medium (Becton
Dickinson) and in liquid 7H9 media (Mycobacterium Growth
Indicator Tubes, Becton Dickinson) for mycobacteria. CSF
cultures were incubated at 37uC for 12 weeks and examined
weekly for growth. All positive CSF cultures were sent to the
Tuberculosis Reference Laboratory at Pham Ngoc Thach
Hospital, Ho Chi Minh City, for identification and drug
susceptibility testing, using the 1% proportion method [25,26].
Drug treatments
Patients previously untreated for tuberculosis received isoniazid
5 mg/kg od po (maximum 300 mg/day), rifampicin 10 mg/kg od
po (maximum 600 mg/day), pyrazinamide 25 mg/kg od po
(maximum 2 g/day) and ethambutol 20 mg/kg od po (maximum
1.2 g/day) for 3 months followed by rifampicin, isoniazid and
pyrazinamide at the same doses for a further 6 months. Patients
who had previously been treated for tuberculosis also received
intramuscular streptomycin 20 mg/kg (maximum 1.2 g/day) for
the first three months, according to Vietnamese national
guidelines. Patients received directly observed therapy during
their inpatient stay (two to three months) and were followed up by
the National Tuberculosis Programme after hospital discharge.
Second-line antituberculous therapy was not available at the time
of the study.
All patients received adjunctive dexamethasone therapy, unless
there were contraindications to corticosteroids. The dose and
duration of dexamethasone depended upon the TBM grade at
presentation: patients with grade I TBM received 0.3 mg/kg/day,
tapered over 6 weeks whereas patients with grade II or grade III
TBM received 0.4 mg.kg/day tapered over 8 weeks [27].
All patients with baseline CD4 count ,200 cells/mm
3 were
prescribed cotrimoxazole prophylaxis. Antiretroviral therapy was
not routinely available at the time of the study. All patients who
survived to hospital discharge were referred to the National HIV
Programme for HIV treatment and care, according to local
procedures.
Data collection
Data were recorded onto individual case record forms, double
entered in an Access database, and checked by the principal
investigator, prior to statistical analysis.
HIV-Associated TB Meningitis
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Clinical and microbial manifestations of HIV-associated TBM
are described using medians with ranges or numbers with
percentages. Median time to death was estimated using Kaplan-
Meier methods and differences between TBM grade groups were
compared using the log rank test. The Wilcoxon-Breslow-Gehan
test of equality was used if the survival lines crossed. Univariate
analysis was conducted using Cox regression to determine which
presenting factors had a significant effect on time to death. To
identify independent predictors for time to death, we entered all
significant variables from the univariate analysis into a Cox
regression model using a backward stepwise approach. The final
model retained only those variables with a p-value less than 0.05.
All statistical analyses were done using STATA, version 9
(StataCorp LP, College Station, Texas, USA).
Role of the funding source
The corresponding author had full access to all the data and had
final responsibility for the decision to submit for publication. The
funding source had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Results
Patient demographics and clinical features
58 patients were enrolled into the study between November
2004 and September 2005. Thirty nine (67.2%) patients died,
eleven patients (19.0%) patients survived, two patients (3.4%)
withdrew from the study and six patients (10.3%) were lost to
follow-up.
The baseline demographic and clinical features are presented in
the first column of table 1. The majority of patients were young,
male, intravenous drug users. In terms of TBM disease severity at
presentation, all three disease severity grades were represented
although the majority of patients had grade III TBM. Most
patients were aware of their HIV diagnosis and had other clinical
features of HIV infection, including generalized lymphadenopa-
thy, oral candidiasis and/or herpes zoster. All patients had World
Health Organization HIV stage 4 disease by virtue of their TBM
diagnosis. Only three patients were taking, or had previously
taken, ART prior to study entry and four patients commenced
ART therapy during the study period.
Comparison of the baseline demographic and clinical features
between patients who died and those who survived are
summarized in table 1. Data from patients who withdrew or were
lost to follow-up were excluded from the comparison of deaths and
survivors. Patients who died were more likely to have a prolonged
duration of illness, lower Glasgow coma score, higher TBM grade
and were less likely to be receiving antiretroviral therapy.
Investigation results
The baseline laboratory variables are presented in the first
column of table 2. Baseline laboratory abnormalities included low
median values for haematocrit, blood lymphocyte percentage,
serum sodium level and CD4 T-lymphocyte count. The median
values for all other baseline blood tests were within the normal
range.
Comparison of baseline laboratory variables between deaths
and survivors are also shown in table 2. Data from patients who
withdrew or were lost to follow-up were excluded from the
comparison of deaths and survivors. Patients who died were more
likely to have a low baseline median serum sodium level than those
who survived.
The results of baseline CSF investigations are summarized in
table 3. Abnormalities included a high CSF white cell count, high
percentage of CSF neutrophils, elevated CSF protein level, low
Table 1. Baseline demographic and clinical features of HIV TBM patients
Variable All patients (n=58) Deaths (n=39) Survivors (n=11)
Age in years, median (range) 26.5 (20–48) 25 (20–48) 32 (20–39)
Male 51 (87.9%) 34 (87.2%) 11 (100%)
Intravenous drug use 46/56 (82.1%) 31 (79.5%) 8 (72.7%)
Commercial sex worker 7/56 (12.5%) 4 (10.3%) 3 (27.2%)
Duration of symptoms, days, median (range) 11 (2–90) 14 (3–90) 7 (2–30)
Past history TB 12/55 (21.8%) 7/36 (19.4%) 4 (36.4%)
Known HIV positive 36/55 (65.5%) 25/37 (67.6%) 7 (63.6%)
Antiretroviral therapy 7 (12.1%) 1 (2.6%) 6 (54.5%)
Clinical features of HIV infection
1 40 (69%) 26 (66.7%) 8 (72.7%)
Weight in kg, median (range) 49.5 (35–60) 48 (38–60) 50 (40–55)
Glasgow coma score 12 (3–15) 10 (3–15) 14 (8–15)
Focal neurology
2 19 (32.8%) 16 (41%) 1 (9.1%)
TBM grade I 14 (24.1%) 7 (17.9%) 5 (45.5%)
TBM grade II 20 (34.5%) 10 (25.6%) 4 (36.4%)
TBM grade III 24 (41.4%) 22 (56.4%) 2 (18.2%)
Confirmed TBM 54 (93.1%) 37 (94.9%) 9 (81.8%)
Probable TBM 4 (6.9%) 2 (5.1%) 2 (18.2%)
Notes: Data are number (%) of patients, unless otherwise noted. Comparison of variables between deaths and survivors excludes patients who withdrew or were lost to
follow-up. TBM grade=British Medical Research Council disease severity grade.
1oral candidiasis, generalized lymphadenopathy, herpes zoster.
2cranial nerve palsies, hemiplegia or paraplegia.
doi:10.1371/journal.pone.0001772.t001
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patients who withdrew or were lost to follow-up were excluded
from the comparison of deaths and survivors. Patients who died
were more likely to have a high CSF neutrophil percentage and a
low CSF lymphocyte percentage.
Forty (69%) CSF samples were smear positive for acid-fast
bacilli by Ziehl-Neelsen stain and 51 (87.9%) CSF samples were
culture positive for mycobacteria. Fourteen (24.1%) isolates were
smear negative but culture positive; three (5.2%) isolates were
smear positive and culture negative. Of the positive mycobacterial
cultures, 49/51 (96.1%) isolates were identified as M. tuberculosis
using the nitrate and reductase tests. Two isolates (3.9%) were
smear and culture positive in our laboratory but were reported as
‘contaminated’ (mixed mycobacterial cultures) by the National
Tuberculosis Reference Laboratory and were not further identi-
fied, according to local procedure.
Drug susceptibility testing results were available for 46 isolates
(table 3). 21/46 (45.7%) CSF isolates were susceptible to all first-
line drugs (rifampicin, isoniazid, pyrazinamide, ethambutol and
streptomycin). 25/46 (54.3%) of CSF isolates had resistance to one
Table 2. Baseline laboratory investigations in HIV TBM patients
Variable Normal range All patients (n=58) Deaths (n=39) Survivors (n=11)
CD4 count, cells/mm
3 500–1500 32 (2–285)
3 31 (2–285) 37 (16–141)
Haematocrit % 37–47 34.8 (19.6–45.1) 34.9 (19.6–45.1) 35.4 (28.8–42.2)
Blood white cell count610
9/l 5–10 8.9 (2.7–21.9) 8.9 (2.7–20.6) 8.7 (3.7–21.9)
Blood neutrophil % 55–75 80.1 (41.6–92.9) 80.6 (41.6–92.9) 80.3 (61.2–91.2)
Blood lymphocyte % 20–40 10.0 (3–47.7) 9.9 (3–47.7) 8.8 (4.3–18.2)
Blood platelet count610
9/l 200–400 244 (75–604) 263 975–604) 235 (94–448)
Serum sodium mmol/l 35–145 127.8 (110–148) 125.7 (110–148) 135 (115–140)
Serum potassium mmol/l 3.5–5.0 3.9 (2.9–5.8) 3.9 (2.9–5.8) 3.9 (3.2–4.7)
Serum creatinine mmol/l 53–120 75.5 (9.4–276) 71 (9.4–276) 80 (53–164)
Serum bilirubin mmol/l #17 8 (1–47)
1 8.3 (1–47) 8 (5–17)
Serum aspartate transaminase IU/l #37 41 (18–599)
2 46 (18–599) 40 (22–158)
Serum alanine transaminase IU/l #40 42 (17–621)
2 41.5 (17–621) 60 (22–240)
Notes: Data are expressed as median (range), unless otherwise noted. Comparison of variables between deaths and survivors excludes patients who withdrew or were
lost to follow-up.
1data from 52 patients.
2data from 55 patients.
3data from 50 patients.
doi:10.1371/journal.pone.0001772.t002
Table 3. Cerebrospinal fluid and microbiology results in HIV TBM patients
Variable Normal range All patients (n=58) Deaths (n=39) Survivors (n=11)
CSF WCC610
9 cells/l #5 438 (0–3960) 431 (0–3960) 340 (66–715)
CSF neutrophils % 0 63 (4–96) 70.5 (6–96) 30 (4–81)
CSF lymphocytes % #5 37 (4–96) 29.5 (4–94) 70 (18–96)
CSF protein g/l #0.4 1.3 (0.43–3.4) 1.23 (0.67–3.4) 1.41 (0.79–1.67)
CSF: blood glucose ratio $0.6 0.3 (0.1–0.8)
1 0.3 (0.1–0.6) 0.4 (0.3–0.8)
CSF lactate mmol/l #1.8 4.8 (1.7–10.2)
2 4.8 (1.7–10.2) 5.1 (2.7–6.7)
Positive Ziehl Neelsen stain 40 (69%) 32 (82.1%) 3 (27.3%)
Positive mycobacterial culture 51 (87.9%) 35 (89.7%) 9 (81.8%)
Isolate fully drug susceptible 21/46 (45.7%) 13/32 (40.6%) 3/8 (37.5%)
Isolate monoresistant 6/46 (13%) 4/32 (12.5%) 2/8 (25%)
Isolate polyresistant 15/46 (32.6%) 11/32 (34.4%) 3/8 (37.5%)
Isolate multidrug resistant 4/46 (8.7%) 4/32 (12.5%) 0/8 (0%)
Isolate resistant to streptomycin 24/46 (52.2%) 18/32 (56.3%) 5/8 (62.5%)
Isolate resistant to isoniazid 19/46 (41.3%) 15/32 (46.9%) 3/8 (37.5%)
Isolate resistant to rifampicin 4/46 (8.7%) 4/32 (12.5%) 0/8 (0%)
Notes: Data are expressed as median (range) or number (%). Comparison of variables between deaths and survivors excludes patients who withdrew or werel o s tt o
follow-up. CSF=cerebrospinal fluid. WCC=white cell count.
1data from 57 patients.
2data from 53 patients.
doi:10.1371/journal.pone.0001772.t003
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(resistance to one first line drug), 14/46 had poly-resistance
(resistance to two drugs other than rifampicin and isoniazid) and
4/46 (8.7%) isolates were MDR (resistance to at least rifampicin
and isoniazid). In terms of resistance to individual drugs: 24/46
(52.2%) isolates were resistant to streptomycin; 19/46 (41.3%)
isolates were resistant to isoniazid and 4/46 (8.7%) isolates were
resistant to rifampicin, all of which were MDR.
Twelve patients had previously been treated for pulmonary or
lymph node tuberculosis. Nine of these were CSF culture positive
and eight had drug susceptibility testing performed. One isolate
was MDR TB, three were resistant to isoniazid and streptomycin
and one had streptomycin monoresistance. One patient who had a
negative CSF culture on admission subsequently grew MDR-TB
from pleural fluid. Comparison of CSF variables between deaths
and survivors is summarized in table 3. The data from the patients
who withdrew or were lost to follow-up were excluded from the
comparison of deaths and survivors. CSF smear positivity,
rifampicin resistance and multidrug resistance were more common
in patients who died than in those who survived.
Outcome
Thirty nine (67.2%) patients died, with an overall median time
to death of 20 days (range 1–172 days) [Figure 1a]. However, the
median time to death varied significantly with TBM grade
(p=0.0002): 88 days for grade 1; 116 days for grade 2; and 6 days
for grade 3 [Figure 1b]. While the survival functions for patient
with TBM grade 1 and 2 were not significantly different (p=0.93),
patients with TBM grade 3 died significantly faster when
compared with patient with TBM grade 1 (p=0.006).
During the course of the study, 10 (17%) patients developed
further AIDS-defining conditions e.g. Pneumocystis jiroveci pneumo-
nia (n=4), cryptococcal meningitis (n=2), Penicillium marneffei
bacteraemia (n=2), oesophageal candidiasis (n=1) and non-
typhoidal salmonella bacteraemia (n=1).
Univariate analysis of baseline characteristics identified seven
factors that were associated with time to death: TBM grade
[Hazard ratio (HR) 2.11, 95% confidence interval (CI )1.33 to
3.34], lack of antiretroviral therapy (HR 0.09, 95% CI 0.01 to
0.68), low baseline GCS (HR 0.85, 95% CI 0.78 to 0.93), low
serum sodium (HR 0.93, 95% CI 0.89 to 0.97), high CSF
neutrophil percentage (HR 1.02, 95% CI 1.01 to 1.04), low CSF
lymphocyte percentage (HR 0.98, 95% CI 0.97 to 0.99) and CSF
smear positive (HR 3.46, 95% CI 1.50 to 7.98).
The multivariate analysis identified three independent predic-
tors for earlier time to death: increased TBM grade [adjusted
hazard ratio (AHR) 1.73, 95% CI 1.08–2.76, p=0.02], lower
serum sodium (AHR 0.93, 95% CI 0.89 to 0.98, p=0.002) and
decreased CSF lymphocyte percentage (AHR 0.98, 95% CI 0.97
to 0.99, p=0.003).
Discussion
There is limited information on the influence of HIV infection
on the clinical presentation, laboratory features and outcome of
TBM. Most studies published to date have been small,
retrospective and have compared the clinical features of TBM in
HIV-infected and uninfected patients. Some studies have reported
that HIV infection does not alter the presenting clinical features of
TBM [28,29], whereas others have suggested that HIV infection is
associated with a higher rate of extra-pulmonary disease [30],
extra-meningeal disease [31,32] and radiological abnormalities on
cranial imaging [32]
In terms of laboratory features of HIV-associated TBM, a
previous study of showed that HIV infection was associated with a
lower CSF leucocyte count and with isoniazid and streptomycin
resistance [33] In another study, 21% of patients had an acellular
CSF, 39.3% had CSF neutrophil predominance, and the CSF
smear was positive in only 5.4% [31]. A prospective study of 123
Indian children (8/123 HIV infected) showed that HIV-infected
children were more likely to have a haemoglobin ,8 g/dl than
uninfected children (OR 12, 95% CI 2.6–55.9, p=0.001) [29].
There is also conflicting data on the effect of HIV infection on
outcome in TBM. Some studies have failed to demonstrate a
significant impact of HIV on inpatient mortality from TBM [2,34–
36], whereas others have reported significantly higher mortality
rates in HIV-infected TBM patients [28,37]. A South African
study reported significantly more treatment failures in the HIV-
infected group suggesting that HIV infection may influence the
response to treatment and the likelihood of relapse [31].
The current study was designed as a prospective descriptive
study, to define the clinical and microbiological features of patients
with HIV-associated TBM in Vietnam. The patients were
predominantly young, male, intravenous drug users, a finding
consistent with previously reported epidemiological data from
Vietnam [23]. Patients presented late with a prolonged duration of
illness, severe TBM disease, as evidenced by a high proportion of
Figure 1. Kaplan-Meier survival estimate for HIV-associated
TBM patients. a) survival curve for all patients. b) survival curve
stratified according to TBM grade
doi:10.1371/journal.pone.0001772.g001
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CD4 counts.
In contrast to previous studies [19,31,33], patients in the current
study often had a high CSF cell count, with neutrophil
predominance. Such findings are more commonly associated with
acute bacterial meningitis and may mislead clinicians, resulting in
a delayed or missed diagnosis of TBM. One possible explanation
for this finding is that TBM may occur as a manifestation of
primary infection in HIV-infected patients, as patients often have a
miliary appearance on chest radiography. However, the CSF
abnormality that was found to be associated with death was a low
CSF lymphocyte percentage. One possible explanation is that
patients with advanced HIV disease usually have low numbers of
lymphocytes in the peripheral blood, which may be reflected in the
low CSF lymphocyte count. In addition, TBM may stimulate
increased HIV replication in the CNS compartment, resulting in
destruction of CSF lymphocytes.
The other abnormality that was associated with death was a low
serum sodium level, which may be a marker of severe TBM
disease. The underlying cause of hyponatraemia in TBM is
unknown but possible explanations include cerebral salt wasting
syndrome, syndrome of inappropriate antidiuretic hormone
secretion (SIADH), or hyponatraemic natriuretic syndrome [38].
The CSF smear and culture positivity rates were also higher
than those reported from previous studies of HIV-associated TBM
[19,28,31,34,35]. This may be because the CSF smears were
performed, using large volumes of CSF (5–10 mls) by a dedicated
technician in a research laboratory. Furthermore the quantity of
bacilli seen in the CSF smear appeared to be higher, with a shorter
time to detection of acid fast bacilli, in HIV-associated TBM than
in HIV-negative TBM (data not shown). One explanation could
be profound immune deficiency resulting in an attenuated
immune response [39] and uncontrolled replication of M.
tuberculosis within the subarachnoid space.
The majority of CSF isolates were identified as M. tuberculosis.
Two isolates were reported as ‘contaminated’ by the regional
reference laboratory, a recognized phenomenon in routine
mycobacterial laboratories where there is high throughput of
samples [40,41].
The drug susceptibility testing results showed high rates of drug
resistance with 54.3% resistance to one or more first line drugs and
8.7% multi-drug resistance. The rates of drug resistance in this
study are considerably higher than those reported in the last
Vietnamese National Drug Resistance Survey, although this was
performed a decade ago. All patients with MDR TBM died, but
streptomycin and/or isoniazid resistance were not associated with
mortality, consistent with previously published data [42] Of the 25
cases of documented drug resistance only eight patients had
previously been treated for tuberculosis, suggesting transmission of
drug resistant TB in this population.
The outcome of HIV-associated TBM was dismal with a 67.2%
mortality rate and a short time to death. The majority of patients
presented with severe TBM and advanced HIV disease, both of
which are known to be associated with poor prognosis [30]. At
presentation all patients underwent investigations of the CSF for
bacterial pathogens and cryptococcal meningitis, all which were
negative. Investigations for viral CNS infections (e.g. polymerase
chain reaction assays for human herpesviruses or JC virus) were
not available at the time of the study. Thus, although the
confirmed diagnostic rates for TBM were high in this study it was
not possible to exclude all potential CNS pathogens. Cranial
imaging was prohibitively expensive for most patients and was
only performed at baseline in six patients (four CT scans and two
MRI scan). The most common abnormalities were meningeal
enhancement, hydrocephalus and cerebral infarcts. Neurosurgical
intervention for TBM was not available at the time of the study.
Another factor that may have contributed to the high observed
mortality rate was the delay in presentation to hospital. The
median duration of symptoms prior to study entry was 11 days
(range 2 to 90 days) and there was a non-significant difference
between deaths and survivors. Once patients were admitted to the
ward antituberculous therapy and adjunctive corticosteroids were
commenced within 24 hours. The decision to commence TB
treatment was based on a positive CSF smear result (69% of which
were positive) or fulfillment of diagnostic criteria for probable
TBM.
Unfortunately, it was not possible to determine the cause of
death in all patients, particularly those who died after hospital
discharge. In view of the observation that 17% of patients
developed other AIDS defining illnesses during the study period, it
is reasonable to speculate that some of these deaths may have been
due to other undiagnosed opportunistic infections. Post-mortem
examinations are rarely performed in Vietnam.
Patients presenting with HIV-associated TBM clearly warrant
antiretroviral therapy and prophylaxis against opportunistic
infections by virtue of their profound immunosuppression.
Although antiretroviral therapy is becoming available in Vietnam
access to treatment is difficult for patients admitted to hospital with
their AIDS-defining illness. At present, access to treatment is
restricted to ambulatory patients who are well enough to attend an
outpatient clinic. Furthermore, there are significant delays
between the diagnosis of HIV infection, referral to the clinic,
adherence training and commencement of antiretroviral therapy.
Thus in 2008, three years after the introduction of antiretroviral
therapy funded by external donor agencies, only 20% of patients
who warrant antiretroviral therapy at our hospital are actually
receiving it.
In this study all patients who survived to hospital discharge were
referred to the National HIV Programme for HIV treatment and
care, according to local policy. The benefits of antiretroviral
therapy are clearly demonstrated by the observation that six of the
seven patients who received antiretroviral therapy survived. The
one patient that died despite receiving antiretroviral therapy had
MDR-TB isolated from pleural fluid.
In conclusion, HIV-associated TBM is a devastating disease and
a number of formidable challenges remain. These include rapid
diagnosis of drug-resistant tuberculosis, determining the optimal
regimens and duration of treatment, determining the optimal time
to initiate antiretroviral therapy, assessing the risks and benefits of
adjunctive corticosteroid therapy in this already severely immu-
nosuppressed population and perhaps, most importantly, ensuring
universal free access to HIV treatment and care. Clinical trials to
answer these questions are urgently required.
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